keyword
https://read.qxmd.com/read/38640331/impact-of-various-anesthetic-regimens-on-motor-evoked-potentials-in-infants-undergoing-spinal-surgery-a-case-series
#21
JOURNAL ARTICLE
Hirofumi Nakahari, Makoto Ikeda, Niall C T Wilton, Michihiro Kurimoto, Taiki Kojima
Motor-evoked potential (MEP) monitoring is commonly used in children. MEP monitoring in infants is difficult due to smaller signals requiring higher stimulation voltages. There is limited information on the effect of different anesthetics on MEP monitoring in this age group. This case series describes the effect of different anesthetic regimens on MEP monitoring in infants. Patients <1 year of age who underwent spinal surgery with MEP monitoring between February 2022 and July 2023 at a single tertiary care children hospital were reviewed...
April 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38640243/liver-targeted-polymeric-prodrugs-delivered-subcutaneously-improve-tafenoquine-therapeutic-window-for-malaria-radical-cure
#22
JOURNAL ARTICLE
Ayumi E Pottenger, Debashish Roy, Selvi Srinivasan, Thomas E J Chavas, Vladmir Vlaskin, Duy-Khiet Ho, Vincent C Livingston, Mahdi Maktabi, Hsiuling Lin, Jing Zhang, Brandon Pybus, Karl Kudyba, Alison Roth, Peter Senter, George Tyson, Hans E Huber, David Wesche, Rosemary Rochford, Paul A Burke, Patrick S Stayton
Approximately 3.3 billion people live with the threat of Plasmodium vivax malaria. Infection can result in liver-localized hypnozoites, which when reactivated cause relapsing malaria. This work demonstrates that an enzyme-cleavable polymeric prodrug of tafenoquine addresses key requirements for a mass administration, eradication campaign: excellent subcutaneous bioavailability, complete parasite control after a single dose, improved therapeutic window compared to the parent oral drug, and low cost of goods sold (COGS) at less than $1...
April 19, 2024: Science Advances
https://read.qxmd.com/read/38640200/multicenter-phase-1-study-of-etavopivat-ft-4202-treatment-for-up-to-12-weeks-in-patients-with-sickle-cell-disease
#23
JOURNAL ARTICLE
Santosh L Saraf, Robert Ward Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz, Frans A Kuypers, R Clark Brown, James Geib, Maria D Ribadeneira, Patricia Schroeder, Eric Wu, Sanjeev Forsyth, Patrick F Kelly, Theodosia A Kalfa, Marilyn J Telen
Etavopivat is an investigational, once-daily, oral, selective erythrocyte pyruvate kinase (PKR) activator. A multicenter, randomized, placebo-controlled, double-blind, 3-part, phase 1 study (https://clinicaltrials.gov/study/NCT03815695) was conducted to characterize the safety and clinical activity of etavopivat. Thirty-six patients with sickle cell disease (SCD) were enrolled into 4 cohorts: one single-dose; two multiple ascending doses; one open-label [OL]. In the OL cohort, 15 patients (median age 33.0 [range, 17‒55] years received 400-mg etavopivat once daily for 12 weeks; 14 completed treatment...
April 19, 2024: Blood Advances
https://read.qxmd.com/read/38639389/propofol-alleviates-anxiety-like-behaviors-associated-with-pain-by-inhibiting-the-hyperactivity-of-pvn-crh-neurons-via-gaba-a-receptor-%C3%AE-3-subunits
#24
JOURNAL ARTICLE
Le Yu, Xiaona Zhu, Kang Peng, Huimin Qin, Kexin Yang, Fang Cai, Ji Hu, Ye Zhang
Pain, a comorbidity of anxiety disorders, causes substantial clinical, social, and economic burdens. Emerging evidence suggests that propofol, the most commonly used general anesthetic, may regulate psychological disorders; however, its role in pain-associated anxiety is not yet described. This study investigates the therapeutic potential of a single dose of propofol (100 mg kg-1 ) in alleviating pain-associated anxiety and examines the underlying neural mechanisms. In acute and chronic pain models, propofol decreased anxiety-like behaviors in the elevated plus maze (EPM) and open field (OF) tests...
April 19, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38639103/effect-of-hepatic-impairment-on-trilaciclib-pharmacokinetics
#25
JOURNAL ARTICLE
Chao Li, Richard A Preston, Emily Dumas, Andrew Beelen, Thomas C Marbury
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of trilaciclib...
April 19, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38638750/an-open-label-single-arm-multicenter-observational-study-evaluating-the-safety-and-effectiveness-of-akynzeo%C3%A2-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-in-india
#26
JOURNAL ARTICLE
Sudeep Gupta, Chandrakanth Mv, Boben Thomas, Ghanshyam Biswas, Sumant Gupta, Palanki S Dattatreya, Sagar Bhagat, Saiprasad Patil, Sumit Bhushan, Hanmant Barkate
Background Chemotherapy-induced nausea and vomiting is a common and unpleasant treatment-related side effect reported by cancer patients receiving chemotherapy. Akynzeo® or NEPA (NEtupitant + PAlonosetron) is the first fixed combination of netupitant and palonosetron that targets both critical pathways involved in emesis while providing a convenient, single oral dose therapy. The current study aimed to assess the effectiveness and safety of NEPA in a real-world setting in India. Methodology This was an open-label, multicenter, prospective, single-arm study conducted at six different locations across India...
March 2024: Curēus
https://read.qxmd.com/read/38638426/a-novel-dual-mechanism-of-action-bispecific-pd-1-il-2v-armed-by-a-%C3%AE-%C3%AE-only-interleukin-2-variant
#27
JOURNAL ARTICLE
Yongji Jiang, Chuyuan Chen, Yuan Liu, Rong Wang, Chuan Feng, Lili Cai, Shuang Chang, Lei Zhao
INTRODUCTION: Interleukin-2 (IL-2) is one of the first cytokines to be discovered as an immune agonist for cancer immunotherapy. Biased IL-2 variants had been discovered to eliminate Treg activation or enhance the tumor specific T cell cytotoxicity. However, all the biased IL-2 variants pose the risk to overstimulate immune response at a low-dose range. Here, we introduce a novel dual-MOA bispecific PD-1-IL-2v molecule with great anti-tumor efficacy in a high dosed manner. METHODS: The novel IL-2 variant was designed by structural truncation and shuffling...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38638401/safety-and-efficacy-of-anlotinib-combined-with-taxane-and-lobaplatin-in-neoadjuvant-treatment-of-clinical-stage-ii-iii-triple-negative-breast-cancer-in-china-the-neoaltal-trial-a-single-arm-phase-2-trial
#28
JOURNAL ARTICLE
Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
BACKGROUND: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1-4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth. It has been proven effective in HER2-negative metastatic breast cancer, but its efficacy in early-stage triple-negative breast cancer (TNBC) is unknown. This phase 2 study aims to evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients with TNBC...
May 2024: EClinicalMedicine
https://read.qxmd.com/read/38638162/hi1a-improves-sensorimotor-deficit-following-endothelin-1-induced-stroke-in-rats-but-does-not-improve-functional-outcomes-following-filament-induced-stroke-in-mice
#29
JOURNAL ARTICLE
Adriana Knezic, Elena Budusan, Natalie J Saez, Brad R S Broughton, Lachlan D Rash, Glenn F King, Robert E Widdop, Claudia A McCarthy
Activation of acid-sensing ion channel 1a (ASIC1a) plays a major role in mediating acidosis-induced neuronal injury following a stroke. Therefore, the inhibition of ASIC1a is a potential therapeutic avenue for the treatment of stroke. Venom-peptide Hi1a, a selective and highly potent ASIC1a inhibitor, reduces the infarct size and functional deficits when injected into the brain after stroke in rodents. However, its efficacy when administered using a clinically relevant route of administration remains to be established...
April 12, 2024: ACS Pharmacology & Translational Science
https://read.qxmd.com/read/38637883/therapeutic-potential-of-targeting-nrf2-by-panobinostat-in-pituitary-neuroendocrine-tumors
#30
JOURNAL ARTICLE
Yijun Cheng, Yuting Dai, Hao Tang, Xingyu Lu, Jing Xie, Wanqun Xie, Qianqian Zhang, Yanting Liu, Shaojian Lin, Hong Yao, Hanbing Shang, Kun Yang, Hongyi Liu, Xuefeng Wu, Jianming Zhang, Xun Zhang, Li Xue, Zhe Bao Wu
We aimed to identify the druggable cell-intrinsic vulnerabilities and target-based drug therapies for PitNETs using the high-throughput drug screening (HTS) and genomic sequencing methods. We examined 9 patient-derived PitNET primary cells in HTS. Based on the screening results, the potential target genes were analyzed with genomic sequencing from a total of 180 PitNETs. We identified and verified one of the most potentially effective drugs, which targeted the Histone deacetylases (HDACs) both in in vitro and in vivo PitNET models...
April 18, 2024: Acta Neuropathologica Communications
https://read.qxmd.com/read/38637844/survival-analysis-after-stereotactic-ablative-radiotherapy-for-early-stage-non-small-cell-lung-cancer-a-single-institution-cohort-study
#31
JOURNAL ARTICLE
Kamila Resova, Lukas Knybel, Tereza Parackova, Marian Rybar, Karel Cwiertka, Jakub Cvek
BACKGROUND: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC), but which patients benefit from stereotactic radiotherapy is unclear. The aim of this study was to analyze prognostic factors for early mortality. METHODS: From August 2010 to 2022, 617 patients with medically inoperable, peripheral or central ES-NSCLC were treated with SABR at our institution. We retrospectively evaluated the data from 172 consecutive patients treated from 2018 to 2020 to analyze the prognostic factors associated with overall survival (OS)...
April 18, 2024: Radiation Oncology
https://read.qxmd.com/read/38637689/dynamics-of-clonal-hematopoiesis-under-dna-damaging-treatment-in-patients-with-ovarian-cancer
#32
JOURNAL ARTICLE
Christopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, Natalia Estrada, Friederike Christen, Ute Martha Moll, Robert Zeillinger, Wolfgang Daniel Schmitt, Jalid Sehouli, Hagen Kulbe, Maximilian Fleischmann, Isabelle Ray-Coquard, Alain Zeimet, Francesco Raspagliesi, Claudio Zamagni, Ignace Vergote, Domenica Lorusso, Nicole Concin, Lars Bullinger, Elena Ioana Braicu, Frederik Damm
Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs). Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein 90 inhibitor (HSP90i) treatment within the phase II EUDARIO trial using error-corrected sequencing of 72 genes...
April 18, 2024: Leukemia
https://read.qxmd.com/read/38637586/immune-response-stability-to-the-sars-cov-2-mrna-vaccine-booster-is-influenced-by-differential-splicing-of-hla-genes
#33
JOURNAL ARTICLE
Cíntia Barros Santos-Rebouças, Cristina Dos Santos Ferreira, Jeane de Souza Nogueira, Otávio José Brustolini, Luiz Gonzaga Paula de Almeida, Alexandra Lehmkuhl Gerber, Ana Paula de Campos Guimarães, Rafael Mina Piergiorge, Cláudio José Struchiner, Luís Cristóvão Porto, Ana Tereza Ribeiro de Vasconcelos
Many molecular mechanisms that lead to the host antibody response to COVID-19 vaccines remain largely unknown. In this study, we used serum antibody detection combined with whole blood RNA-based transcriptome analysis to investigate variability in vaccine response in healthy recipients of a booster (third) dose schedule of the mRNA BNT162b2 vaccine against COVID-19. The cohort was divided into two groups: (1) low-stable individuals, with antibody concentration anti-SARS-CoV IgG S1 below 0.4 percentile at 180 days after boosting vaccination; and (2) high-stable individuals, with antibody values greater than 0...
April 18, 2024: Scientific Reports
https://read.qxmd.com/read/38637530/characterizing-heterogeneous-single-cell-dose-responses-computationally-and-experimentally-using-threshold-inhibition-surfaces-and-dose-titration-assays
#34
JOURNAL ARTICLE
Patrick C Kinnunen, Brock A Humphries, Gary D Luker, Kathryn E Luker, Jennifer J Linderman
Single cancer cells within a tumor exhibit variable levels of resistance to drugs, ultimately leading to treatment failures. While tumor heterogeneity is recognized as a major obstacle to cancer therapy, standard dose-response measurements for the potency of targeted kinase inhibitors aggregate populations of cells, obscuring intercellular variations in responses. In this work, we develop an analytical and experimental framework to quantify and model dose responses of individual cancer cells to drugs. We first explore the connection between population and single-cell dose responses using a computational model, revealing that multiple heterogeneous populations can yield nearly identical population dose responses...
April 18, 2024: NPJ Systems Biology and Applications
https://read.qxmd.com/read/38637521/sars-cov-2-booster-vaccine-dose-significantly-extends-humoral-immune-response-half-life-beyond-the-primary-series
#35
JOURNAL ARTICLE
Chapin S Korosec, David W Dick, Iain R Moyles, James Watmough
SARS-CoV-2 lipid nanoparticle mRNA vaccines continue to be administered as the predominant prophylactic measure to reduce COVID-19 disease pathogenesis. Quantifying the kinetics of the secondary immune response from subsequent doses beyond the primary series and understanding how dose-dependent immune waning kinetics vary as a function of age, sex, and various comorbidities remains an important question. We study anti-spike IgG waning kinetics in 152 individuals who received an mRNA-based primary series (first two doses) and a subset of 137 individuals who then received an mRNA-based booster dose...
April 18, 2024: Scientific Reports
https://read.qxmd.com/read/38637495/the-activity-and-immune-dynamics-of-pd-1-inhibition-on-high-risk-pulmonary-ground-glass-opacity-lesions-insights-from-a-single-arm-phase-ii-trial
#36
JOURNAL ARTICLE
Bo Cheng, Caichen Li, Jianfu Li, Longlong Gong, Peng Liang, Ying Chen, Shuting Zhan, Shan Xiong, Ran Zhong, Hengrui Liang, Yi Feng, Runchen Wang, Haixuan Wang, Hongbo Zheng, Jun Liu, Chengzhi Zhou, Wenlong Shao, Yuan Qiu, Jiancong Sun, Zhanhong Xie, Zhu Liang, Chenglin Yang, Xiuyu Cai, Chunxia Su, Wei Wang, Jianxing He, Wenhua Liang
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein significantly improve survival in patients with advanced non-small-cell lung cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions remains unclear. This is a single-arm, phase II trial (NCT04026841) using Simon's optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients with persistent high-risk (Lung-RADS category 4 or had progressed within 6 months) GGOs...
April 19, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38637352/short-sleep-duration-and-smoking-initiation-in-university-students-a-retrospective-cohort-study
#37
JOURNAL ARTICLE
Qinyan Li, Ryohei Yamamoto, Maki Shinzawa, Naoko Otsuki, Yuichiro Matsumura, Yuko Nakamura, Masayuki Mizui, Isao Matsui, Yusuke Sakaguchi, Haruki Shinomiya, Chisaki Ishibashi, Hiroyoshi Adachi, Kaori Nakanishi, Izumi Nagatomo
PURPOSE: The aim of this study was to clarify an association between short sleep duration and smoking initiation. METHODS: Participants eligible for this retrospective cohort study were university students who were admitted to a single national university in Japan between 2007 and 2015. Baseline sleep duration and smoking status were measured using general questionnaires at health checkups at admission. During a 6-year observation period, smoking initiation was assessed using general questionnaires at annual health checkups...
April 19, 2024: Sleep & Breathing
https://read.qxmd.com/read/38637213/exploring-covid-19-vaccine-uptake-and-hesitancy-among-vulnerable-populations-in-inner-city-vancouver-canada-insights-into-characteristics-and-clinical-outcomes
#38
JOURNAL ARTICLE
Saina Beitari, Shana Yi, Shawn Sharma, Rossitta Yung, Brian Conway
The COVID-19 pandemic is having a profound impact on the health, social and economic well-being of people in Canada and around the world. To address vaccine disparity among vulnerable populations facing social-structural challenges, it is crucial to provide evidence-based information on the importance of completion of the recommended vaccination schedule. In this study, we investigated vaccination rates and variables as facilitators or barriers to COVID-19 vaccination among vulnerable populations living in Vancouver's inner-city residents...
April 17, 2024: Vaccine
https://read.qxmd.com/read/38637211/immunogenicity-and-safety-of-a-14-valent-pneumococcal-polysaccharide-conjugate-vaccine-pneubevax-14%C3%A2-administered-to-6-8%C3%A2-weeks-old-healthy-indian-infants-a-single-blind-randomized-active-controlled-phase-iii-study
#39
JOURNAL ARTICLE
Ramesh V Matur, Subhash Thuluva, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Kamal Thammireddy, Piyush Paliwal, Niranjana S Mahantshetty, Mandyam Dhati Ravi, S Prashanth, Savita Verma, Jai Prakash Narayan
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing pneumococcal vaccines, particularly impacting pediatric and elder population. In addition, the regions where the PCV is not available, the disease burden remains high. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14™; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) was evaluated in infants in comparison to licensed vaccine, Prevenar-13 (PCV-13)...
April 17, 2024: Vaccine
https://read.qxmd.com/read/38637132/multisite-prospective-study-of-perioperative-pain-management-practices-for-anterior-cruciate-ligament-reconstruction-in-adolescents-society-for-pediatric-anesthesia-improvement-network-spain-project-report
#40
JOURNAL ARTICLE
Kesavan Sadacharam, James S Furstein, Steven J Staffa, Galaxy Li, Rami Karroum, Jocelyn M Booth, Eugene Kim, Suzanne M McCahan, Wallis T Muhly, Vidya Chidambaran
INTRODUCTION: Although 200 000 adolescents undergo anterior cruciate ligament reconstruction (ACLR) surgery annually, no benchmarks for pediatric post-ACLR pain management exist. We created a multicenter, prospective, observational registry to describe pain practices, pain, and functional recovery after pediatric ACLR. METHODS: Participants (n=519; 12-17.5 years) were enrolled from 15 sites over 2 years. Data on perioperative management and surgical factors were collected...
April 18, 2024: Regional Anesthesia and Pain Medicine
keyword
keyword
118322
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.